ERBB2 and breast cancer: The site-specifically IRDye800CW- and IRDye680RD-labeled nanobodies 11A4 and B9, respectively targeting HER2 and carbonic anhydrase IX (CAIX), showed accumulation in breast cancer lesions (DCIS) and lung metastasis in an experimental setup mimicking the surgical setting [121,122].